IRIS Accounts Production v26.1.10.61 15316256 director 1.1.25 31.12.25 31.12.25 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh153162562024-12-31153162562025-12-31153162562025-01-012025-12-31153162562023-11-28153162562023-11-292024-12-31153162562024-12-3115316256ns15:EnglandWales2025-01-012025-12-3115316256ns14:PoundSterling2025-01-012025-12-3115316256ns10:Director12025-01-012025-12-3115316256ns10:PrivateLimitedCompanyLtd2025-01-012025-12-3115316256ns10:SmallEntities2025-01-012025-12-3115316256ns10:AuditExempt-NoAccountantsReport2025-01-012025-12-3115316256ns10:SmallCompaniesRegimeForDirectorsReport2025-01-012025-12-3115316256ns10:SmallCompaniesRegimeForAccounts2025-01-012025-12-3115316256ns10:FullAccounts2025-01-012025-12-3115316256ns10:CompanySecretary12025-01-012025-12-3115316256ns10:RegisteredOffice2025-01-012025-12-3115316256ns5:CurrentFinancialInstruments2025-12-3115316256ns5:CurrentFinancialInstruments2024-12-3115316256ns5:ShareCapital2025-12-3115316256ns5:ShareCapital2024-12-3115316256ns5:RetainedEarningsAccumulatedLosses2025-12-3115316256ns5:RetainedEarningsAccumulatedLosses2024-12-3115316256ns5:WithinOneYearns5:CurrentFinancialInstruments2025-12-3115316256ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-31
REGISTERED NUMBER: 15316256 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 December 2025

for

Venipharm Ltd

Venipharm Ltd (Registered number: 15316256)






Contents of the Financial Statements
for the Year Ended 31 December 2025




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Venipharm Ltd

Company Information
for the Year Ended 31 December 2025







DIRECTOR: E Mauger





SECRETARY: Pramex International Ltd





REGISTERED OFFICE: 8th Floor South
11 Old Jewry
London
EC2R 8DU





REGISTERED NUMBER: 15316256 (England and Wales)






Venipharm Ltd (Registered number: 15316256)

Balance Sheet
31 December 2025

31.12.25 31.12.24
Notes £ £
CURRENT ASSETS
Debtors 4 468,712 166,073
Cash at bank 75,593 128,159
544,305 294,232
CREDITORS
Amounts falling due within one year 5 495,370 282,430
NET CURRENT ASSETS 48,935 11,802
TOTAL ASSETS LESS CURRENT
LIABILITIES

48,935

11,802

CAPITAL AND RESERVES
Called up share capital 10,000 10,000
Retained earnings 38,935 1,802
SHAREHOLDERS' FUNDS 48,935 11,802

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Venipharm Ltd (Registered number: 15316256)

Balance Sheet - continued
31 December 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 25 June 2026 and were signed by:





E Mauger - Director


Venipharm Ltd (Registered number: 15316256)

Notes to the Financial Statements
for the Year Ended 31 December 2025

1. STATUTORY INFORMATION

Venipharm Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Amount are rounded to the nearest £.

Going concern
The company is dependent upon the continued financial support of its parent company
which has undertaken to financially support the company for the at least 12 months after the
date of the signing of these accounts and for the foreseeable future.
The financial statements have therefore been prepared on a going concern basis.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2024 - 1 ) .

Venipharm Ltd (Registered number: 15316256)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2025

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.25 31.12.24
£ £
Trade debtors 82,962 -
Amounts owed by group undertakings 306,152 155,482
Other debtors 79,598 10,591
468,712 166,073

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.25 31.12.24
£ £
Trade creditors 36,347 13,745
Amounts owed to group undertakings 409,506 242,023
Taxation and social security 12,732 927
Other creditors 36,785 25,735
495,370 282,430

6. RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland, not to disclose related party transactions with wholly owned subsidiaries within the group.

7. ULTIMATE CONTROLLING PARTY

The immediate parent undertaking is Calonne SAS, a company registered in France. The
address of its registered office is 4 Bureaux de la colline, Saint cloud, France, 92210.